...
首页> 外文期刊>Breast cancer research and treatment. >Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility
【24h】

Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility

机译:RAD51C基因在遗传性乳腺癌和卵巢癌易感性中的贡献的进一步证据

获取原文
获取原文并翻译 | 示例
           

摘要

RAD51C, a RAD51 paralogue involved in homologous recombination, is a recently established Fanconi anemia and breast cancer predisposing factor. In the initial report, RAD51C mutations were shown to confer a high risk for both breast and ovarian tumors, but most of the replication studies published so far have failed to identify any additional susceptibility alleles. Here, we report a full mutation screening of the RAD51C gene in 147 Finnish familial breast cancer cases and in 232 unselected ovarian cancer cases originating from Finland and Sweden. In addition, in order to resolve whether common RAD51C SNPs are risk factors for breast cancer, we genotyped five tagging single nucleotide polymorphisms, rs12946522, rs304270, rs304283, rs17222691, and rs28363312, all located within the gene, from 993 Finnish breast cancer cases and 871 controls for cancer associated variants. Whereas, none of the studied common SNPs associated with breast cancer susceptibility, mutation analysis revealed two clearly pathogenic alterations. RAD51C c.-13-14del27 was observed in one familial breast cancer case and c.774delT in one unselected ovarian cancer case, thus confirming that RAD51C mutations are implicated in breast and ovarian cancer predisposition, although their overall frequency seems to be low. Independent identification of the very recently reported RAD51C c.774delT mutation in yet another patient originating from Sweden suggests that it might be a recurrent mutation in that population and should be studied further. The reliable estimation of the clinical implications of carrying a defective RAD51C allele still requires the identification of additional mutation positive families.
机译:RAD51C是参与同源重组的RAD51旁系同源物,是最近发现的范可尼贫血和乳腺癌的诱发因素。在最初的报告中,RAD51C突变被证明对乳腺和卵巢肿瘤均具有高风险,但是迄今为止发表的大多数复制研究都未能鉴定出任何其他易感性等位基因。在这里,我们报告了147个芬兰家族性乳腺癌病例和232个来自芬兰和瑞典的未选择的卵巢癌病例中RAD51C基因的完整突变筛选。此外,为了确定常见的RAD51C SNP是否是乳腺癌的危险因素,我们对来自993个芬兰乳腺癌病例的5个标记单核苷酸多态性rs12946522,rs304270,rs304283,rs17222691和rs28363312进行了基因分型。 871个与癌症相关的变异体的对照。鉴于没有研究过的与乳腺癌易感性相关的常见SNP,突变分析揭示了两个明显的致病性改变。在一个家族性乳腺癌病例中观察到RAD51C c.-13-14del27,在一个未选择的卵巢癌病例中观察到c.774delT,因此证实RAD51C突变与乳腺癌和卵巢癌易感性有关,尽管它们的总体发生率似乎较低。在另一位来自瑞典的患者中对最近报道的RAD51C c.774delT突变的独立鉴定表明,它可能是该人群中的复发性突变,应进一步研究。携带有缺陷的RAD51C等位基因的临床意义的可靠估计仍需要鉴定其他突变阳性家族。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号